GHRH and GH secretagogues: Clinical perspectives and safety

Pediatric Endocrinology Reviews

Volumn 2, Issue SUPPL. 1, 2004, Pages 86-92

  Aimaretti, Gianluca ^a   Baldelli, Roberto ^a,b   Corneli, Ginevra ^a   Bellone, Simonetta ^b   Rovere, Silvia ^a   Croce, Chiara ^a   Ragazzoni, Federico ^a   Giordano, Roberta ^a   Arvat, Emanuela ^a   Bona, Gianni ^b   Ghigo, Ezio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Adolescence; Adulthood; Aging; Childhood; GH; GH deficiency; Provocative tests

Indexed keywords

ALENDRONIC ACID; ARGININE; GALANIN; GHRELIN; GHRELIN DERIVATIVE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR[1-29]; GROWTH HORMONE RELEASING HORMONE DERIVATIVE; GROWTH HORMONE SECRETAGOGUE; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; IBUTAMOREN; PROPRANOLOL; PYRIDOSTIGMINE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADULT DISEASE; AGING; CARPAL TUNNEL SYNDROME; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; FLUID RETENTION; GERIATRIC DISORDER; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONE RESPONSE; HUMAN; HYPERGLYCEMIA; INSULIN TOLERANCE TEST; METABOLIC DISORDER; NONHUMAN; POSTMENOPAUSE OSTEOPOROSIS; PROVOCATION TEST; REVIEW; SIDE EFFECT; SOMATIC CELL; SOMATOPAUSE;

ADULT; CHILD; GROWTH DISORDERS; GROWTH HORMONE-RELEASING HORMONE; HUMAN GROWTH HORMONE; HUMANS;

EID: 19944432751     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285-288
2. de Boer H, Blok GJ, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocr Rev 1995;16:63-86
3. Shimon I. Growth hormone replacement for adult growth hormone deficiency. Expert Opin Pharmacother 2003;4:1977-1983
4. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6
5. Growth Hormone Research Society (GRS). Consensus guidelines for the diagnosis and treatment of adults with GH deficiency. Statement of the GRS workshop on adult GHD. J Clin Endocrinol Metab 1998;83:379-381
6. Abs R. Update on the diagnosis of GH deficiency in adults. Eur J Endocrinol 2003;148 Suppl 2:S3-8
7. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab 2000;85:3990-3993
8. Marcus R, Holloway L, Butterfield G. Clinical uses of growth hormone in older people. J Reprod Fertil Suppl 1993;46:115-118
9. Savine R, Sonksen P. Growth hormone-hormone replacement for the somatopause? Horm Res 2000;53 Suppl 3:37-41
10. Toogood AA. Growth hormone (GH) status and body composition in normal ageing and in elderly adults with GH deficiency. Horm Res 2003;60(Suppl 1):105-111
11. Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, Schilling LM, Cole KY, Skiles EH, Pezzoli SS, Hartman ML, Veldhuis JD, Gormley GJ, Thorner MO. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 1996;81(12):4249-4257
12. Chapman IM, Pescovitz OH, Murphy G, Treep J, Cerchio KA, Krupa D, Gertz S, Polvino WJ, Skiles EH, Pezzoli SS, Thorner MO. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults. J Clin Endocrinol Metab 1997;82:3455-3463
13. Arvat E, Giordano R, Gianotti L, Broglio F, Camanni F, Ghigo E. Neuroendocrinology of the human growth hormone-insulin-like growth factor I axis during ageing. Growth Horm IGF Res 1999;9 Suppl A:111-5
14. Ghigo E, Arvat E, Aimaretti G, Broglio F, Giordano R, Camanni F. Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects. Baillieres Clin Endocrinol Metab 1998;12:341-358
15. van der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004;25:426-457
16. Ghigo E, Aimaretti G, Arvat E, Camanni F. Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults. Endocrine 2001;15:29-38
17. Shalet SM, Toogood A, Rahim A, Brennan BMD. The diagnosis of growth hormone deficiency in children and adults. Endocr Rev 1998;19:203-223
18. Valetto MR, Bellone J, Baffoni C, Savio P, Aimaretti G, Gianotti L, Arvat E, Camanni F, Ghigo E. Reproducibility of the growth hormone response to stimulation with growth hormone releasing hormone plus arginine during lifespan. Eur J Endocrinol 1996;135:135-138
19. Baldelli R, Otero XL, Camina JP, Gualillo O, Popovic V, Dieguez C, Casanueva FF. Growth hormone secretagogues as diagnostic tools in disease states. Endocrine 2001;14:95-99
20. Ghigo E, Aimaretti G, Gianotti L, Bellone J, Arvat E, Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol 1996;134:352-356
21. Laron Z. Growth hormone secretagogues. Clinical experience and therapeutic potential. Drugs 1995;50:595-601
22. Darzy KH, Aimaretti G, Wieringa G, Gattamaneni HR, Ghigo E, Shalet SM. The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J Clin Endocrinol Metab 2003;88:95-102
23. AACE medical guidelines for clinical practice for growth hormone use in adults and children. Update endocrine practice 2003;9:64-76
24. Hoffman DM, O'Sullivan AJ, Baxter RC, Ho KKY. Diagnosis of growth-hormone deficiency in adults. Lancet 1994;343:1064-1068
25. Aimaretti G, Corneli G, Baldelli R, Di Somma C, Gasco V, Durante C, Ausiello L, Rovere S, Grottoli S, Tamburrano G, Ghigo E. Diagnostic reliability of a single IGF-I measurement in 237 adults with total anterior hypopituitarism and severe GH deficiency. Clin Endocrinol 2003;59:56-61
26. Aimaretti G, Baffoni C, DiVito L, Bellone S, Grottoli S, Maccario M, Arvat E, Camanni F, Ghigo E. Comparisons among old and new provocative tests of GH secretion in 178 normal adults. Eur J Endocrinol 2000;142:347-352
27. Aimaretti G, Cornell G, Razzore P, Bellone S, Baffoni C, Arvat E, Camanni F, Ghigo E. Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone+arginine as provocative tests for the diagnosis of GH deficiency in adults. J Clin Endocrinol Metab 1998;83:1615-1618
28. Iranmanesh A, Veldhuis JD. Clinical pathophysiology of the somatotropic (GH) axis in adults. Endocrinol Metab Clin North Am 1992:21:783-816
29. Veldhuis JD, Anderson SM, Shah N, Bray M, Vick T, Gentili A, Mulligan T, Johnson ML, Weltman A, Evans WS, Iranmanesh A. Neurophysiological regulation and target-tissue impact of the pulsatile mode of growth hormone secretion in the human. Growth Horm IGF Res 2001;11 Suppl A:S25-37
30. Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev 1991;12:424-449
31. Lewis UJ, Sinha YN, Haro LS. Variant forms and fragments of human growth hormone in serum. Acta Paediatr Suppl 1994;399:29-31
32. Strobl JS, Thomas MJ. Human growth hormone. Pharmacol Rev 1994;46:1-34
33. Boguszewski CL. Molecular heterogeneity of human GH: from basic research to clinical implications. J Endocrinol Invest 2003;26:274-288
34. Arvat E, Broglio F, Aimaretti G, Benso A, Giordano R, Deghenghi R, Ghigo E. Ghrelin and synthetic GH secretagogues. Best Pract Res Clin Endocrinol Metab 2002;16:505-517
35. Penalva A, Baldelli R, Camina JP, Cerro AL, Micic D, Tamburrano G, Dieguez C, Casanueva FF. Physiology and possible pathology of growth hormone secretagogues. J Pediatr Endocrinol Metab. 2001;14 Suppl 5:1207-12
36. Laron Z. Intranasally and orally active GH secretagogues are useful clinical tools: so why are they not on the market? J Endocrinol Invest 2003;26:91-92
37. Camanni F, Ghigo E, Arvat E. Growth hormone-releasing peptides and their analogs. Front Neuroendocrinol 1998;19:47-72
38. Toogood AA, O'Neill PA, Shalet SM. Beyond the somatopause: growth hormone deficiency in adults over the age of 60 years. J Clin Endocrinol Metab 1996;81:460-465
39. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993;14(1):20-39
40. Rosen CJ. Growth hormone and aging. Endocrine 2000;12(2):197-201
41. Bouillanne O, Rainfray M, Tissandier O, Nasr A, Lahlou A, Cnockaert X, Piette F. Growth hormone therapy in elderly people: an age-delaying drug? Fundam Clin Pharmacol 1996;10(5):416-30
42. Svensson J. The importance of growth hormone (GH) and GH secretagogues for bone mass and density. Curr Pharm Des 2002;8(23):2023-32
43. Ghigo E, Arvat E, Gianotti L, Lanfranco F, Broglio F, Aimaretti G, Maccario M, Camanni F. Hypothalamic growth hormone-insulin-like growth factor-I axis across the human life span. J Pediatr Endocrinol Metab 2000;13 Suppl 6:1493-502
44. Muller EE, Cocchi D, Ghigo E, Arvat E, Locatelli V, Camanni F. Growth hormone response to GHRH during lifespan. J Pediatr Endocrinol 1993;6(1):5-13
45. Ghigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP, Boghen MF, Deghenghi R, Camanni F. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. Eur J Endocrinol 1996;135(4):407-12
46. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]-growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997;82(5):1472-9
47. Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. J Clin Endocrinol Metab 1994;79(5):1440-3
48. Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, Stevens T, Bellantoni MF, Rogers MA, Baumann G, Roth J, Harman SM, Spencer RG. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997;4 6(1):89-96
49. Xhorram O, Yeung M, Vu L, Yen SS. Effects of [norleucine27] growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women. J Clin Endocrinol Metab 1997;82(11):3590-6
50. Ghigo E, Arvat E, Camanni F. Orally active growth hormone secretagogues: state of the art and clinical perspectives. Ann Med 1998;30(2):159-68
51. Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ; MK-677/Alendronate Study Group. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2001;86(3):1116-25